-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep Reaches 50% Enrollment Milestone in Global Phase III TACTI-004 Trial for First-Line NSCLC

Reuters·02/05/2026 23:53:18

Please log in to view news